Clinical Trial: A Neoadjuvant Study of Sintilimab Plus Platinum Doublet Chemotherapy in IIIA(N2) Stage NSCLC

U.S., April 10 -- ClinicalTrials.gov registry received information related to the study (NCT04840290) titled 'A Neoadjuvant Study of Sintilimab Plus Platinum Doublet Chemotherapy in IIIA(N2) Stage NSCLC' on March 30.

Brief Summary: The purpose of this neoadjuvant study is to compare Sintilimab plus chemotherapy in terms of safety and effectiveness in treating resectable NSCLC of stage IIIA (N2) This study has multiple primary endpoints.

Study Type: Interventional

Condition: Non Small Cell Lung Cancer

Intervention: Drug: Biological: Sintilimab Drug: Cisplatin Drug: Paclitaxel for Injection (Albumin Bound) Drug: Carboplatin

Biological: Sintilimab Drug: Cisplatin Drug: Paclitaxel for Injection (Albumin Bound) Drug: Carboplatin

Recruitmen...